ストックスクリーナーアプリを入手
0.4312
5.35%
0.0219
アフターアワーズ：
.79
0.3588
+83.21%
前日終値:
$0.4093
開ける：
$0.4221
24時間の取引高:
37.43M
Relative Volume:
29.99
時価総額：
$20.96M
収益：
$1.14M
当期純損益:
$-56.27M
株価収益率:
-0.3552
EPS:
-1.2139
ネットキャッシュフロー:
$-51.94M
1週間 パフォーマンス:
+11.71%
1か月 パフォーマンス:
+17.17%
6か月 パフォーマンス:
-35.66%
1年 パフォーマンス:
-65.23%
1日の値動き範囲:
$0.4033
$0.44
1週間の範囲:
$0.3866
$0.44
52週間の値動き範囲:
$0.27
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.4312 | 19.89M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-24 | 開始されました | Wedbush | Outperform |
| 2023-06-06 | 再開されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-25 | 開始されました | Evercore ISI | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-25 | 開始されました | Jefferies | Buy |
| 2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
$Werewolf Therapeutics (HOWL.US)$ - Moomoo
Werewolf Therapeutics (HOWL) Q2 2026 Earnings: EPS Delivers 130.17% Surprise, Stock Moves HigherGuidance Update - Vinanet
Werewolf Therapeutics Inc (NASDAQ: HOWL) Share Price, HOWL Stock News, HOWL Share Price & Updates - Kalkine
Werewolf Therapeutics Company Profile & Introduction - moomoo.com
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Werewolf Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Price to sales forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL - TradingView
Price to book forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL - TradingView
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Werewolf Therapeutics (HOWL) Plunges 27.8% to $0.36 as Biotech Stock Tests Critical SupportStop Run - dars.gov.et
Werewolf Therapeutics, Inc. (HOWL) Q2 2026 Financial Results: Key Risks, Losses, and Strategic Outlook - Minichart
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewswire
HOWL Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Werewolf Therapeutics Inc (HOWL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Werewolf Therapeutics Inc (HOWL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Werewolf Therapeutics (HOWL) Stock Forum and Discussion - Moomoo
HOWL|Werewolf Therapeutics Inc|Price:0.427|Chg%:+0.067 - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Werewolf Therapeutics Inc (HOWL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Werewolf Therapeutics, Inc. Revenue Breakdown – NASDAQ:HOWL - TradingView
Werewolf Therapeutics (HOWL) Surges 18.55% as Shares Approach Key Resistance at $0.45Composite Profile - Vinanet
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HOWL stock gains on latest Wolfpack earnings context - Ad-hoc-news.de
HOWL stock trades on fresh data from Werewolf Therapeutics cancer pipeline - Ad-hoc-news.de
HOWL Q1 2026 Earnings: Narrower Loss Surprises as Biotech Advances PipelinePost-Earnings Drift - Vinanet
Werewolf Therapeutics (HOWL) Q1 2026 Earnings: Narrower Loss Surprises as Biotech Navigates Early Pipeline MilestonesRevenue Report - dars.gov.et
Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL - TradingView
Frontier tech research, news & data - MLQ.ai
HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline - ad-hoc-news.de
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Nigeria
Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - ad-hoc-news.de
Form 144 Werewolf Therapeutics For: 6 July By Investing.com - Investing.com Nigeria
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Werewolf Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclinePre-Earnings Setup - dars.gov.et
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com Australia
Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
1.86%
大文字化:
|
ボリューム (24 時間):